Background: The t(14;18)(q32;q21) is the most commonly observed chromosomal
Introduction
Non-Hodgkin lymphoma (NHL) is the 5 th most common cancer overall in the United
States, and the lifetime odds of developing NHL is 1 in 45 for men and 1 in 53 for women (1) .
The remarkable rise in incidence of NHL over the last 50 years suggests a major role for environmental factors in the etiology of this cancer. However, established risk factors to date account for only a relatively small fraction of the cases (2).
The (t14;18)(q32;q21) is a hallmark translocation in follicular lymphoma (3) , one of the most common lymphoma subtypes (2) . With this translocation event, BCL2 becomes fused to the immunoglobulin heavy chain (IgH) locus, leading to constitutive Bcl-2 expression and apoptosis inhibition under the control of the IgH enhancer (4, 5) . Under normal conditions, lymphocytes must strictly regulate growth and apoptosis to provide adequate immunologic defenses against infections while not overwhelming the organism with inappropriate cell numbers. With the (t14;18)(q32;q21) and other less commonly observed translocations of genes in the apoptosis pathway observed among lymphoma cases (6, 7) , it is clear that dysregulation of the balance between cell proliferation and programmed cell death is a central feature in lymphomagenesis (8) . Furthermore, evidence that the (t14;18)(q32;q21)
translocation is also present in approximately 30% of diffuse large B-cell lymphomas (DLBCL) and 1-2% of chronic lymphocytic leukemias / small lymphocytic lymphomas (CLL/SLL) (6) , and the deletion/down-regulation of Bcl-2 inhibiting micro-RNA species (mir-15 and mir-16) in CLL (9) , suggests a broad role for bcl-2 and apoptosis in lymphoma.
Bcl-2 is a member of a large family of pro-and anti-apoptotic proteins which coordinate both extrinsic and intrinsic cell signals to activate caspases, the effector enzymes necessary for apoptosis execution (4, 5, 10) . The high prevalence of the t(14;18) translocation among healthy individuals, estimated as high at 66% at age 50, would indicate that perhaps over-expression of the Bcl-2 protein as a result of this transformation may not sufficient for malignant transformation (11) (12) (13) . There is accumulating evidence that other Bcl-2 family proteins,
The above mentioned studies have primarily focused on genetic events that effect expression or function of apoptotic proteins within the tumor. However, accumulating epidemiologic evidence suggests that germline genetic variation also plays a role in NHL etiology (19) (20) (21) . Common variation related to B-cell growth and survival (22), inflammation and immune function (23) (24) (25) (26) (27) (28) , and DNA repair (29) has been linked to NHL risk. Furthermore, recent genome wide association (GWA) studies have identified novel SNPs that are associated with risk of developing CLL and FL (30, 31) . To our knowledge, only one other group has comprehensively evaluated the role of germline genetic variation in the apoptosis pathway with regard to NHL etiology, including 8 BCL2 family members and 12 caspase family members in a pooled analysis of three independent case-control studies with a total of 1946 cases and 1808 controls (32, 33). Statistically significant gene-level associations of BCL2L11, CASP1, CASP8, and CASP9 with NHL risk were identified.
Here, we independently evaluated the hypothesis that germline genetic variation in genes from the apoptosis pathway is associated with risk of developing NHL, and compare these results to those reported in the pooled study in an attempt to validate the relevance of this pathway in NHL etiology. The 36 candidate genes evaluated (Table 1 and Supplemental Table   1 ) are known to be pro-or anti-apoptotic, and are represented in both the intrinsic and extrinsic apoptotic pathways.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research 6 genotyping details and quality control measures for both of these genotyping platforms have been previously described (27, 28 Table 2 ); since no genotype calling errors were identified, these SNPs were not excluded from analysis. We previously found no evidence of population stratification in our data (27) . 
Results
Participant characteristics. There were 441 cases and 475 controls available for analysis. For cases, the mean age was 60.1 years and 58% were male, while for controls the mean age was 61.7 years and 55% were male. Additional patient characteristics have been previously published (28) . The most common NHL subtypes were SLL/CLL (N=123), FL (N=113), and DLBCL (N=69).
Gene-level analysis. We first evaluated gene-level associations between the 36 candidate apoptosis pathway genes and NHL, all subtypes combined. Using principal components analysis, we observed 4 genes to be significantly associated with NHL risk at 0.079 and 0.34); however, they appear to represent the same signal when jointly modeled. That is, when we added either rs2020902 or rs2042370 to the logistic regression model with the most significant SNP, rs6685648, the added SNP was non-significant based on the likehood ratio test 3, 4, 5, 6, 7, 10) , 2 genes (CASP1 and CASP8) that were associated with NHL risk in the pooled study but were not associated with NHL risk in our study, and 2 genes (BCL2L11 and CASP9) that were significantly associated at the gene-level with NHL risk in both studies. For these two genes (BCL2L11 and CASP9), we compared individual SNP-level significance (based on ordinal ORs) between these two studies.
The results for the overlapping observed and imputed SNPs are presented in Table 4 . Figure 1 illustrates the relative position and linkage disequilibrium (based on HapMap CEPH population genotypes) of each BCL2L11 (Panel A) and CASP9 (Panel B) genotyped SNPs.
For BCL2L11, there was no overlap in the SNPs genotyped in the two studies. For the Mayo case-control study, we imputed genotypes for the 4 SNPs observed to be significantly associated with NHL risk in the pooled study (rs7567444, rs3789068, rs686952, and rs6760053). The estimated NHL risk with variant allele copies was similar in direction and magnitude across all four SNPs, and reached significance for rs3789038 (p trend =0.0018) and rs6760053 (p trend =0.0031). In exploratory analyses of these four SNPs by NHL subtype, we observed that the association between the imputed SNP genotypes in the Mayo population were strongest in the CLL/SLL subtype but were also observed in follicular lymphoma at a magnitude consistent with the pooled study, which observed an association specific to the follicular lymphoma subtype ( Table 5 ).
The CASP9 SNP rs2020902 was genotyped in both studies, although the results were inconsistent. The observed association between copies of the variant G allele and NHL risk observed to be significantly associated with NHL risk in the pooled study (rs4661636 and rs4646047), and the magnitude and direction of the estimate associated with Mayo imputed genotypes was consistent for both. An inverse association with the number of variant T alleles at both rs4661636 and rs4646047 was observed in both studies, although associations did not reach significance in the Mayo case-control study.
The pooled study did not genotype BCLAF or BAG5, so we were not able to compare our findings for these two genes. Further, we did not have the original genotyping data from the pooled analysis, so we were not able to impute genotypes in their population for comparison to SNPs significant in the Mayo case-control study.
Discussion
In this case-control study, we demonstrate gene-and SNP-level association of BCL2L11 (BIM), BCLAF1, BAG5, and CASP9 with NHL risk that remained noteworthy after accounting for multiple testing. While the pFDR q-values estimated for BCL2L11 and CASP9 SNPs do indicate that there is a moderate chance that any of these associations individually may be false positives, the tail strength estimates indicated that the distribution of p-values for the group of SNPs from these genes is more extreme than we would have expected by chance alone.
Moreover, the significant gene-level associations for BCL2L11 and CASP9 were consistent with previously published data from a pooled analysis of three studies (NCI-SEER, Connecticut, and New South Wales) that included 1946 cases and 1808 controls (32, 33). While there was minimal overlap in the individual tagSNPs genotyped across our study and the pooled study, we were able to impute genotypes for the SNPs in our study that were not directly observed, and we found associations that were largely consistent in magnitude and direction across all four significant BCL2L11 SNPs and 2 of 3 CASP9 SNPs from the pooled study, making this the first Strengths of our study include a carefully designed case-control study, central pathology review, and high quality genotyping. Although this study was not population-based, both case and control participation was restricted to those residing in the region surrounding Mayo Clinic (Minnesota, Iowa, and Wisconsin), thus minimizing the effect of referral bias, and increasing the internal validity of using frequency-matched general medicine controls from the same region.
Common HapMap SNPs were used to tag genes of interest, and through other genotyping projects we have ruled out the presence of significant population stratification (27) . The major limitations are the use of an exclusively Caucasian population, which limits generalizability, and the relatively small sample size, which in particular precludes robust estimation of NHL subtype associations. There are several apoptosis genes evaluated in this study for which the genotyped tagSNPs provided <70% gene coverage, and thus an association between these genes and NHL risk cannot yet be ruled out. In addition, there are greater than 100 human genes more broadly identified with apoptosis pathway involvement in which germline variants may play a role in NHL risk, including genes with caspase-recruitment domains, death domains, and death effector domains (43) . The genes in the current analysis represent only the core of a larger set of genes involved in apoptosis-related pathways.
The two genes that replicated have strong biologic plausibility in NHL pathogenesis.
BCL2L11 balances the anti-apoptotic influence of BCL2 and coordinates pro-apoptotic signaling through the intrinsic apoptosis pathway (4). In addition, BCL2L11 is required for negative selection of autoreactive lymphocytes (44) . Functional silencing of BCL2L11 through methylation has been observed in Burkitt lymphoma cell lines and primary tumor biopsies, and reduced BCL2L11 mRNA and protein expression has also been documented in other tumors including renal cell carcinoma, melanoma, and colon cancer (45 CASP9, the other gene to be replicated, is a pro-apoptotic protease integral to the intrinsic apoptotic pathway, and is responsible for effector caspase activation and apoptosis execution following activation by Apaf-1 bound to cytochrome c released from mitochondria (46) . Hyperphosphorylation of caspase-9 may lead to aberrant apoptosis inhibition, and the relevance of this process has been demonstrated in a number of other cancer types (46) . Also of note, upon mitochondrial release of cytochrome c via both the intrinsic and extrinsic apoptosis pathways, the cytoplasmic protein Apaf-1 binds caspase-9 to form the apoptosome, in turn activating the caspase cascade (4). APAF1 did not reach gene-level statistical significance in our population, although 6 of the 13 genotyped tagSNPs in this gene were significant at p<0.05.
Given the gene-level significance of CASP9, there may be some clinical relevance of the individual tagSNPs significance in APAF1, and further follow-up on this gene is warranted.
To our knowledge, this is the first report of an association between germline variation in BAG5 and BCLAF1 with regard to lymphoma risk. BCLAF1 and BAG5 are both Bcl-2 family members that suppress BAX (pro-apoptotic) gene expression, in turn suppressing the APAF1 gene and inhibiting apoptosis (4, 47) . These associations should be confirmed in follow-up with an independent study population.
While underpowered to assess NHL subtypes, our data provide some evidence that there may be subtype-specific associations in the apoptosis pathway, particularly BCL2L11 and CASP9. Evidence of differential association of germline variants in the BCL2 and CASP families was observed in the pooled analysis of 3 case-control studies (32, 33), although the ; *SNP function as defined in dbSNP: c-ns, coding-non-synonymous, c-s, coding-synonymous; int, intronic; l-r, variation in region of gene, but not in transcript; mrna-utr, variation in mrna transcript, but not in coding region interval; utr, variation in transcript, but not in coding region interval; ^ ORs adjusted for age and sex. 
